Kay Bross Named Program Director, Member & Vendor Relations, SAFE-BioPharma Association

Kay Bross Named Program Director, Member & Vendor Relations, SAFE-BioPharma Association

FT. LEE, N.J.--(BUSINESS WIRE)--Mar 9, 2010 - Kay Bross has been named Program Director, Member and Vendor Relations for SAFE-BioPharma Association, the non-profit association that created and manages the SAFE-BioPharma® digital identity and digital signature standard for the pharmaceutical and healthcare industries.

Ms. Bross, who served as a member of the association's Board of Directors, is responsible for building and managing relationships with the association's growing member and vendor-partner communities. She also is responsible for business development and alliance management. SAFE-BioPharma members include many of the world's largest biopharmaceutical companies and, increasingly, smaller companies that want to benefit from the time and cost-saving efficiencies of the SAFE-BioPharma standard.

"We are fortunate that Kay Bross is available at this point in the association's development. As a former member of our board and someone who understands both the standard and the community it serves, she will be a valuable asset to the association's development," said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.

Kay Bross is an authority in the area of electronic document management (EDM). She recently retired from Procter & Gamble, where she managed operations associated with Regulatory submissions data and developed the company's corporate intranet virtual library. As a member of P&G's Global Business Solutions, Information Security unit, she introduced the SAFE-BioPharma standard.

Ms. Bross also is recognized in the international EDM community. She co-chaired several annual Drug Information Association (DIA) Electronic Document Management Conferences and served on numerous DIA program committees. She is a frequent EDM speaker and panelist. She has served as a member of the SAFE-BioPharma Board of Directors.

Ms. Bross holds an MEd from Xavier University, Cincinnati and a BA from Emporia State University, Emporia, Ks.

About SAFE-BioPharma Association (www.safe-biopharma.org) SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries. It provides users with a secure, enforceable, and regulatory compliant way to verify identities of parties involved in electronic transactions and to apply digital signatures to electronic documents.

The Association's members include:

 

    * Abbott (NYSE: ABT)
    * Amarin Corp. (NASDAQ: AMRN)
    * Amgen (NASDAQ: AMGN)
    * AstraZeneca (NYSE: AZN)
    * Bristol-Myers Squibb (NYSE: BMY)
    * GlaxoSmithKline (NYSE: GSK)
    * Johnson & Johnson (NYSE: JNJ)
    * Eli Lilly (NYSE: LLY)
    * McDougall Scientific
    * Merck (NYSE: MRK)
    * MWB Consulting Limited
    * National Notary Association
    * Novartis (NYSE: NVS)
    * Oxford Outcomes
    * Pfizer (NYSE: PFE)
    * Premier Inc.
    * Roche
    * Sanofi-Aventis (NYSE: SNY)
    * ScheringPlough-Organon (NYSE: SGP)
    * SNAP Diagnostics

SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

Contact: SAFE-BioPharma Association
Jon Weisberg
M 801-860-9977
O 801-359-9977
Jo[email protected]

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.